Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belapectin + ipilimumab
- Development stage
- Unknown
- Lead developer
- Galectin Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Belapectin + ipilimumab is a combination immunotherapy regimen being investigated for the treatment of metastatic melanoma. Belapectin (formerly GR-MD-02) is a complex carbohydrate polymer derived from citrus pectin that acts as an inhibitor of galectin-3, a protein often overexpressed in the tumor microenvironment that facilitates immune evasion and tumor progression. Ipilimumab is a recombinant human monoclonal antibody that blocks Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4), a checkpoint molecule that inhibits T-cell activity. The combination therapy, developed through a collaboration between Galectin Therapeutics and Providence Health & Services, aims to enhance the anti-tumor immune response by simultaneously blocking CTLA-4 and inhibiting the immunosuppressive effects of galectin-3, thereby promoting the proliferation and activation of CD8+ T cells within the tumor milieu.
- Brand names
- Yervoy
- Other names
- GR-MD-02 + ipilimumabbelapectin + ipilimumab
02
Targets
LGALS3 (Galectin-3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on belapectin + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belapectin + ipilimumab.